Profile data is unavailable for this security.
About the company
Scisparc Ltd, former Therapix Biosciences Ltd is a Israel-based pharmaceutical company commited into creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The company is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
- Revenue in USD (TTM)0.00
- Net income in USD-6.96m
- Incorporated2004
- Employees3.00
- LocationScisparc Ltd20 Raul Wallenberg Street, Tower ATEL AVIV-YAFO 6971916IsraelISR
- Phone+972 36103100
- Fax+972 36167056
- Websitehttps://scisparc.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NovAccess Global Inc | 0.00 | -1.74m | 535.23k | 1.00 | -- | -- | -- | -- | -0.1193 | -0.1193 | 0.00 | -0.2246 | 0.00 | -- | -- | 0.00 | -1,836.30 | -2,185.89 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -177.93 | -- | -- | -- |
| Hanyuan Biotech International Inc | 10.65m | 3.14m | 539.39k | -- | 0.0294 | 0.0064 | 0.1481 | 0.0506 | 0.2246 | 0.2246 | 0.7611 | 1.03 | -- | -- | -- | -- | -- | -- | -- | -- | 68.54 | -- | 29.51 | -- | 13.36 | 25.66 | 0.00 | -- | 50.51 | -- | 106.71 | -- | -- | -- |
| Better Therapeutics Inc | 0.00 | -31.57m | 548.48k | 54.00 | -- | -- | -- | -- | -1.16 | -1.16 | 0.00 | -0.2449 | 0.00 | -- | -- | 0.00 | -162.15 | -- | -378.28 | -- | -- | -- | -- | -- | -- | -15.18 | 3.27 | -- | -- | -- | 1.43 | -- | -- | -- |
| Molecular Pharmacology (USA) Ltd | 0.00 | -105.18k | 599.73k | 0.00 | -- | -- | -- | -- | -0.0009 | -0.0009 | 0.00 | -0.0188 | 0.00 | -- | -- | -- | -976.60 | -1,219.29 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 44.29 | -- | -- | -- |
| Capstone Holding Corp | 0.00 | -358.00k | 646.20k | 2.00 | -- | -- | -- | -- | -6.58 | -38.12 | 0.00 | -60.70 | 0.00 | -- | -- | -- | -113.46 | 141.94 | -199.60 | 173.06 | -- | -- | -- | -- | -- | -2.92 | -- | -- | -- | -- | 52.46 | -- | -- | -- |
| Scisparc Ltd | 0.00 | -6.96m | 658.85k | 3.00 | -- | 27.05 | -- | -- | -1.22 | -1.51 | 0.00 | 0.0344 | 0.00 | -- | -- | 0.00 | -92.51 | -69.39 | -152.41 | -111.07 | -- | -- | -- | -527.17 | -- | -- | 0.9371 | -- | 113.73 | -- | -97.61 | -- | -- | -- |
| Comera Life Sciences Holdings Inc | 1.00m | -9.35m | 697.75k | 12.00 | -- | -- | -- | 0.6975 | -0.4901 | -0.4901 | 0.0512 | 0.0033 | 0.2498 | -- | 5.08 | 83,367.50 | -224.98 | -- | -1,094.30 | -- | 73.52 | -- | -900.55 | -- | -- | -- | 0.00 | -- | 97.95 | -- | -237.10 | -- | -- | -- |
| International Stem Cell Corp | 7.83m | -327.00k | 720.40k | 29.00 | -- | -- | -- | 0.092 | -0.0409 | -0.0409 | 0.9785 | 0.0045 | 1.46 | 2.53 | 11.87 | 270,069.00 | -5.81 | -29.22 | -68.13 | -73.82 | 58.58 | 59.49 | -3.97 | -21.01 | 0.4672 | -6.06 | 0.9898 | -- | -4.78 | -6.82 | 60.42 | -- | -34.45 | -- |
| Bellerophon Therapeutics Inc | 5.64m | -9.25m | 733.96k | 18.00 | -- | 0.1971 | -- | 0.1301 | -0.8353 | -0.8353 | 0.5054 | 0.3044 | 0.6414 | -- | -- | 313,333.30 | -105.23 | -55.57 | -165.94 | -77.33 | -- | -- | -164.06 | -- | -- | -- | 0.00 | -- | -- | -- | -11.69 | -- | -- | -- |
Data as of May 31 2024. Currency figures normalised to Scisparc Ltd's reporting currency: US Dollar USD
2.76%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Yorkville Advisors Global LPas of 27 Feb 2024 | 55.29k | 2.26% |
| UBS Securities LLCas of 31 Mar 2024 | 8.96k | 0.37% |
| RhumbLine Advisers LPas of 31 Mar 2024 | 3.46k | 0.14% |
Data from 31 Mar 2024 - 15 May 2024Source: FactSet Research Systems Inc.
